A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

A lung adenocarcinoma patient with co-mutations of MET and EGFR exon20 insertion responded to crizotinib

Abstract Background Targeted therapy has revolutionized the treatment of patients with malignancies harboring mutations in driver genes and has brought a favorable survival benefit to the population with actionable oncogenic mutations. In recent years, the MET exon14 skipping mutation has been recog...

Full description

Bibliographic Details
Main Authors: Yan Chen, Bo Jiang, Yuange He, Chu Zhang, Wenjie Zhou, Cheng Fang, Dejian Gu, Minxia Zhang, Mei Ji, Juntao Shi, Xin Yang
Format: Article
Language:English
Published: BMC 2022-06-01
Series:BMC Medical Genomics
Subjects:
NCSLC
MET mutation
EGFR mutation
Double mutation
Crizotinib
Online Access:https://doi.org/10.1186/s12920-022-01291-z

Internet

https://doi.org/10.1186/s12920-022-01291-z

Similar Items